Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy

• Published in: Journal of the American Society of Nephrology Vol. 8; no. 7; pp. 1140 - 1146
• Main Authors: BURNS, G. C, PAUL, S. K, TOTH, I. R, SIVAK, S. L
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.07.1997
• Subjects: AIDS-Associated Nephropathy - drug therapy; AIDS-Associated Nephropathy - metabolism; AIDS-Associated Nephropathy - pathology; AIDS/HIV; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive agents; Biological and medical sciences; Cardiovascular system; Creatinine - blood; Female; Fosinopril - therapeutic use; Glomerulonephritis; HIV-1; Humans; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Nephrotic Syndrome - drug therapy; Nephrotic Syndrome - metabolism; Nephrotic Syndrome - pathology; Pharmacology. Drug treatments; Proteinuria - drug therapy; Time Factors; Kidney disease; Creatinine; Human; Immunopathology; Urinary system disease; Renal function; Treatment efficiency; AIDS; Immune deficiency; Infection; Concomitant disease; Nephropathy; Viral disease; Fosinopril; ACE inhibitor

Angiotensin-converting enzyme inhibition (ACEI) delays progression of diabetic and nondiabetic renal disease. This study examined the effect of fosinopril, 10 mg by mouth daily, in HIV-associated nephropathy (HIV-AN). Twenty patients with HIV-AN were studied. Of 11 patients with non-nephrotic-range...